New insights into further treatment options of cancer

A team from Yale University found through recombinant rat proteins that melanoma cells and white blood cells fuse to form a metastatic mixture. This finding further explains the spread of melanoma and other cancers, providing new insights into further treatment options.

When the malignant cells from a primary tumor spread to other tissues and organs, the cancer becomes deadly. The team analyzed tumor biopsies in patients with malignant melanoma who had undergone bone marrow transplants prior to cancer, comparing DNA from primary melanoma to lymph node DNA after cancer spread. In both cases, they found a mixture of the patient's own DNA and the donor's DNA.

The presence of this hybrid DNA is intense on the surface, which generally attacks cancer cells rather than fused leukocytes, forming a genetic mixture after diffusion.

These findings can serve as new cancer treatment targets. "We need to focus on how leukocytes and cancer cells fuse, and this process involves many steps. These steps are our goals. Future therapy can be designed to prevent bone marrow-derived fusion cells. These studies are focused on the new technology pathways of discovery of targeted metastasis itself," the researchers conclude. Flarebio offers high-quality recombinant proteins including recombinant Nrg2 at competitive prices.